Cerus shows quality below the engine's floor despite 24% revenue growth and overbought momentum, with recent insider selling and analysts still modeling meaningful upside.
Thesis pillars
- Weak Core Profitability→Stable
- Revenue Growth Momentum→Stable
- Overbought Technical Setup→Stable
- +2 more pillars — see the Why tab for full reasoning
Cerus Corporation (CERS) Stock Analysis
Inst Constrain edge
Healthcare · Medical Devices
Sell if holding. Engine safety override at $3.23: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10 and A.R:R 1.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 10%; Below-average business quality.
Cerus Corporation is a biomedical products company commercializing the INTERCEPT Blood System, which uses proprietary chemistry to inactivate blood-borne pathogens in donated platelets, plasma, and red blood cells before transfusion. The platelet, plasma, and cryoprecipitation... Read more
Sell if holding. Engine safety override at $3.23: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10 and A.R:R 1.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 10%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 6.0/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 30d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
About Cerus Corporation
About Cerus Corporation
Cerus Corporation commercializes the INTERCEPT Blood System's platelet, plasma, and cryoprecipitation (IFC) products, which carry FDA approval and CE Mark certification and are sold across the U.S., Europe, the CIS, the Middle East, and Latin America. The red blood cell system remains in Phase 3 development, with the U.S. RedeS study completing enrollment of 689 patients in the fourth quarter of 2025 after a 2024 European certification setback. Cerus manufactures its disposable kits through sole supplier Fresenius Kabi under an agreement running through 2031.
Cerus sells the platelet and plasma systems through a direct sales force and distributors, and shifted its IFC go-to-market in 2026 from selling finished therapeutic doses to hospitals toward selling disposable kits directly to blood centers. In the U.S., the market is highly concentrated among a small number of blood collection organizations, and the company's ability to sustain market penetration depends largely on utilization and distribution by the American Red Cross, the largest single blood collector; the Red Cross currently lacks the capacity to produce IFC for its own accounts and instead depends on Cerus or other blood centers to supply it. In Europe, Germany, France, and England represent Cerus's largest markets, with adoption gated by national bodies such as Germany's Paul Ehrlich Institute and multi-year public-procurement contracts like the one with France's Établissement Français du Sang that carry no purchase-volume commitments. On June 5, 2026, Cerus refinanced its credit facilities with MidCap Financial, drawing an initial $35.0 million against a $65.0 million term loan to repay $30.0 million of existing debt, with a further $30.0 million available in minimum $5.0 million tranches.
Show full overview
Cerus's U.S. commercial results are structurally tied to a single counterparty's purchasing decisions rather than a broad hospital customer base: the American Red Cross represents the largest single share of the U.S. blood collection market, and the 10-K states the company's ability to achieve significant U.S. market penetration is largely dependent on the Red Cross's utilization and distribution of INTERCEPT-treated components. Because the Red Cross cannot yet produce IFC for its own accounts, Cerus's IFC revenue there depends on continuing to win that supply relationship, and any change in the Red Cross's order pace — whether from inventory rebuilding, competing priorities, or new business-continuity or ESG requirements it might impose on suppliers — would make Cerus's near-term results difficult to predict independent of underlying blood-safety demand.
See also: Healthcare · Medical Devices
From Cerus Corporation's most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-06Recent Developments — Cerus Corporation
Material events (past 30 days)
- 8K Jun 8, 2026 MEDIUM Item 1.02: Cerus entered into Second Amended and Restated Term Loan and Revolving Loan Credit Agreements with MidCap Financial on June 5, 2026, refinancing its March 2023 credit facilities. The new Term Loan Credit Agreement provides up to $65.0 million, with an initial $35.0 million draw used to repay $30.0 m
Generated 2026-07-06T20:41:43Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierFresenius Kabi10-K Item 1: 'we rely solely on Fresenius Kabi AG, or Fresenius, for the manufacture of disposable kits for the platelet and plasma systems.'
- HIGHCustomerAmerican Red Cross10-K Item 1A: 'Our ability to achieve and maintain significant market penetration in the U.S. is largely dependent on utilization of INTERCEPT and distribution of INTERCEPT-treated blood components by the American Red Cross.'
- HIGHProductINTERCEPT Blood System (platelets, plasma, cryoprecipitation)10-K Item 1A: 'We depend substantially upon the commercial success of the INTERCEPT Blood System for platelets, plasma and cryoprecipitation in the U.S.'
Material Events(8-K, last 90d)
- 2026-06-08Item 1.02MEDIUMCerus entered into Second Amended and Restated Term Loan and Revolving Loan Credit Agreements with MidCap Financial on June 5, 2026, refinancing its March 2023 credit facilities. The new Term Loan Credit Agreement provides up to $65.0 million, with an initial $35.0 million draw used to repay $30.0 million of existing term debt and a further $30.0 million available in minimum $5.0 million tranches.SEC filing →
- 2026-06-03Item 5.02LOWAt the June 2, 2026 Annual Meeting, stockholders approved an amendment and restatement of the Company's 2024 Equity Incentive Plan as described in the April 22, 2026 proxy statement.SEC filing →
- 2026-04-21Item 5.02LOWThe Board adopted a new Severance Plan on April 17, 2026 for CFO Kevin D. Green, COO Vivek Jayaraman, CMO Richard Benjamin, and Chief Legal Officer Chrystal N. Jensen, superseding prior severance arrangements. The plan pays 18 months' salary (24 months for Jayaraman if he becomes CEO) plus a bonus multiple upon a covered termination within 12 months of a change of control.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Unprofitable operations — net margin -4.4%. Quality floor flags this regardless of sector context.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $3.23: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10 and A.R:R 1.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 10%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $2.94. Score 6.0/10, moderate confidence.
Take-profit target: $3.97 (+25.6% upside). Prior stop was $2.94. Stop-loss: $2.94.
Concentration risk — Supplier: Fresenius Kabi; Concentration risk — Customer: American Red Cross; Quality below floor (3.1 < 4.0).
Cerus Corporation trades at a P/E of N/A (forward N/A). TrendMatrix value score: 8.7/10. Verdict: Sell.
9 analysts cover CERS with a consensus score of 4.2/5. Average price target: $5.
What does Cerus Corporation do?Cerus Corporation is a biomedical products company commercializing the INTERCEPT Blood System, which uses proprietary...
Cerus Corporation is a biomedical products company commercializing the INTERCEPT Blood System, which uses proprietary chemistry to inactivate blood-borne pathogens in donated platelets, plasma, and red blood cells before transfusion. The platelet, plasma, and cryoprecipitation (IFC) systems are FDA-approved and sold across the U.S., Europe, and other regions, while the red blood cell system remains in Phase 3 development after a 2024 setback in its European certification application. Cerus relies solely on Fresenius Kabi to manufacture its disposable kits and depends heavily on the American Re